[{"address1": "450 East 29th Street", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10016", "country": "United States", "phone": "646 860 7985", "website": "https://meiragtx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.", "fullTimeEmployees": 387, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alexandria  Forbes Ph.D.", "age": 58, "title": "CEO, President & Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 2888582, "exercisedValue": 0, "unexercisedValue": 510047}, {"maxAge": 1, "name": "Mr. Richard Brian Giroux B.A.", "age": 50, "title": "COO & CFO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 2138800, "exercisedValue": 0, "unexercisedValue": 472877}, {"maxAge": 1, "name": "Dr. Stuart  Naylor Ph.D.", "age": 60, "title": "Chief Development Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1062146, "exercisedValue": 0, "unexercisedValue": 181562}, {"maxAge": 1, "name": "Mr. Robert J. Wollin J.D.", "age": 47, "title": "General Counsel & Secretary", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michel  Michaelides M.D.", "title": "Head of Clinical Ophthalmology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine Elise Sheehy", "age": 55, "title": "Senior Vice President of Global Integration", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tim  Randall", "title": "Senior Vice President of Risk & Internal Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alastair  Leighton Ph.D.", "title": "Senior Vice President of Manufacturing & Supply Chain", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert K. Zeldin M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1097400, "exercisedValue": 0, "unexercisedValue": 525000}], "auditRisk": 2, "boardRisk": 3, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.94, "open": 3.95, "dayLow": 3.87, "dayHigh": 3.99, "regularMarketPreviousClose": 3.94, "regularMarketOpen": 3.95, "regularMarketDayLow": 3.87, "regularMarketDayHigh": 3.99, "beta": 1.29, "forwardPE": 4.5581393, "volume": 309285, "regularMarketVolume": 309285, "averageVolume": 192025, "averageVolume10days": 140890, "averageDailyVolume10Day": 140890, "bid": 3.88, "ask": 3.97, "bidSize": 100, "askSize": 100, "marketCap": 302562080, "fiftyTwoWeekLow": 3.49, "fiftyTwoWeekHigh": 7.6, "priceToSalesTrailing12Months": 37.252163, "fiftyDayAverage": 4.3816, "twoHundredDayAverage": 5.343175, "currency": "USD", "enterpriseValue": 243292736, "floatShares": 25087975, "sharesOutstanding": 77184200, "sharesShort": 1771196, "sharesShortPriorMonth": 1572538, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0229, "heldPercentInsiders": 0.24247, "heldPercentInstitutions": 0.54028, "shortRatio": 7.88, "shortPercentOfFloat": 0.031600002, "bookValue": 1.237, "priceToBook": 3.1689572, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -93144000, "trailingEps": -1.42, "forwardEps": 0.86, "pegRatio": 0.38, "enterpriseToRevenue": 29.955, "enterpriseToEbitda": -1.567, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MGTX", "underlyingSymbol": "MGTX", "shortName": "MeiraGTx Holdings plc", "longName": "MeiraGTx Holdings plc", "firstTradeDateEpochUtc": 1528464600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "934d1a61-2bc1-31ce-acc9-153361189a8b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.92, "targetHighPrice": 36.0, "targetLowPrice": 9.0, "targetMeanPrice": 20.6, "targetMedianPrice": 20.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 99974000, "totalCashPerShare": 1.54, "ebitda": -155308992, "totalDebt": 87565000, "quickRatio": 2.237, "currentRatio": 2.357, "totalRevenue": 8122000, "debtToEquity": 109.403, "revenuePerShare": 0.13, "returnOnAssets": -0.3666, "returnOnEquity": -0.91512, "freeCashflow": -67232872, "operatingCashflow": -95158000, "revenueGrowth": -0.92, "grossMargins": 1.0, "operatingMargins": -162.79787, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]